In 2023, around ***** thousand cases of ********* were reported by medical institutions in Japan, representing the highest number in the last decade and at the same time, the most common STD in Japan. In the same year, the recorded cases of **************** amounted to about 9.47 thousand.

In 2021, around **** cases of chlamydia were reported on average per medical institution in Japan, representing the highest point in the last decade. That year, the number of herpes genitalis saw a slight decrease to **** reported cases on average.

The Japanese STD devices market is booming, projected to reach $1 billion by 2033 with a 5.92% CAGR. This in-depth analysis covers market size, key players (Reckitt Benckiser, Cooper Surgical, etc.), and future trends in condom, IUD, and other contraceptive device sales in Japan. Recent developments include: In July 2022, Zenbird launched the pocket contraceptive class for educational use at schools and pharmacies. It is a teaching kit that provides contraception awareness in an easy-to-understand manner. Professionals like nurses and pharmacists can provide individual guidance to consultants by showing contraceptive items. Because such kits are not distributed in Japan, the project team designed it by referencing 'Contraceptive Kits' used overseas. They have developed a kit so users can learn by actually seeing and touching the samples., In December 2021, Cooper Surgical, Inc. completed the acquisition of Generate Life Sciences. This acquisition helps Cooper to improve their reproductive segment.. Key drivers for this market are: Increasing Awareness about Sexually Transmitted Diseases (STDs), Rising Rate of Unintended Pregnancies. Potential restraints include: Increasing Awareness about Sexually Transmitted Diseases (STDs), Rising Rate of Unintended Pregnancies. Notable trends are: Condoms are Expected to Dominate the Market Over the Forecast Period.

Snapshot img

Sexually Transmitted Diseases (STD) Treatment Market Size 2025-2029

The sexually transmitted diseases treatment market size is valued to increase USD 24.21 billion, at a CAGR of 7% from 2024 to 2029. Increasing prevalence of STDs will drive the sexually transmitted diseases (std) treatment market.

Major Market Trends & Insights

North America dominated the market and accounted for a 47% growth during the forecast period.
By Type - Viral infections segment was valued at USD 36.7 billion in 2023
By Route Of Administration - Oral segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Market Opportunities: USD 70.93 million
Market Future Opportunities: USD 24205.20 million
CAGR : 7%
North America: Largest market in 2023

Market Summary

The market encompasses a continually evolving landscape driven by the increasing prevalence of these conditions and advances in rapid diagnosis. Core technologies, such as nucleic acid amplification tests and point-of-care diagnostics, play a pivotal role in enhancing the accuracy and speed of STD detection. Applications of these technologies span various service types, including telemedicine, hospitals, and clinics. Despite advancements, challenges persist, including limited healthcare services in developing regions and the emergence of drug-resistant strains. Looking forward, opportunities abound, particularly in the development of novel therapeutics and vaccines.
As of 2021, the global market for STD diagnostics is estimated to account for approximately 20% of the overall infectious disease diagnostics market share. Related markets such as HIV and Hepatitis C virus (HCV) diagnostics also contribute significantly to the overall landscape. The ongoing evolution of the STD Treatment Market underscores the importance of staying informed and prepared for the future.

What will be the Size of the Sexually Transmitted Diseases (STD) Treatment Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Sexually Transmitted Diseases (STD) Treatment Market Segmented and what are the key trends of market segmentation?

The sexually transmitted diseases (STD) treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Viral infections
  Bacterial infections
  Others


Route Of Administration

  Oral
  Topical
  Injectable


End-user

  Hospital and clinics
  Diagnostic centers
  Individuals


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    Spain
    UK


  APAC

    China
    India
    Japan


  Rest of World (ROW)

By Type Insights

The viral infections segment is estimated to witness significant growth during the forecast period.

The market experiences significant growth due to the rising prevalence of viral infections, such as genital herpes caused by the herpes simplex virus, human papillomavirus (HPV) leading to genital warts and cervical cancer, hepatitis B, and AIDS caused by HIV. According to the Centers for Disease Control and Prevention (CDC), around 42-45% of adults aged 18-59 years in the US were infected with HPV during 2023 and 2024. Innovations in STD treatment include the development of combination therapies, rapid diagnostic tests, and antiviral therapies. Safe sex practices, such as condom usage, and public health initiatives focusing on STD testing methods, contact tracing, and disease surveillance contribute to market expansion.

However, challenges like drug interactions, antibiotic resistance, and healthcare disparities persist. Immune response plays a crucial role in treatment efficacy. Antiviral therapies and drug delivery systems aim to improve treatment adherence and patient outcomes. Molecular diagnostics and prevention strategies, such as HPV vaccination, sexual health education, and behavioral interventions, are essential in mitigating the long-term complications of STDs. The market for bacterial infections, such as gonorrhea and syphilis, also experiences growth due to the increasing incidence of these diseases. Pharmacokinetic modeling and treatment efficacy studies are ongoing to address the microbial pathogenesis and improve patient care.

The STD treatment market is expected to grow by approximately 12% in the next two years, with a similar expansion rate anticipated in the following period. The increasing prevalence of STDs, advancements in diagnostic tools, and the development of new treatment methods are key factors driving this growth. Additionally, the market is projected to reach a value of around 25 billion USD by 2026. In conclusion, the sexually transmitted diseases treatment market is a dynamic and evolving indu

In 2022, around **** thousand cases of syphilis were reported in Japan, representing the highest number in the last decade. Syphilis is a sexually transmitted disease that is caused by bacteria.

Snapshot img

Sexually Transmitted Disease (STD) Testing Market Size 2024-2028

The sexually transmitted disease (std) testing market size is valued to increase USD 32.37 billion, at a CAGR of 5.6% from 2023 to 2028. Increasing prevalence of STDs will drive the sexually transmitted disease (std) testing market.

Major Market Trends & Insights

North America dominated the market and accounted for a 48% growth during the forecast period.
By Product - Laboratory testing device segment was valued at USD 53.60 billion in 2022
By Disease Type - Chlamydia segment accounted for the largest market revenue share in 2022

Market Size & Forecast

Market Opportunities: USD 64.43 billion
Market Future Opportunities: USD 32.37 billion
CAGR : 5.6%
North America: Largest market in 2022

Market Summary

The market encompasses the global industry dedicated to diagnosing and identifying various sexually transmitted infections. This market is marked by continuous evolution, driven by the increasing prevalence of STDs and advances in rapid diagnosis technologies. According to the World Health Organization, approximately one million sexually transmitted infections occur every day.
This underscores the growing demand for reliable and accessible testing solutions. However, challenges persist, particularly in developing regions where limited healthcare services hinder widespread testing and treatment. Despite these hurdles, opportunities abound for innovations in core technologies, such as point-of-care diagnostics and molecular testing, as well as in applications, including telemedicine and self-testing. These trends are shaping the future of the STD Testing Market, offering significant potential for growth and impact.

What will be the Size of the Sexually Transmitted Disease (STD) Testing Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Sexually Transmitted Disease (STD) Testing Market Segmented and what are the key trends of market segmentation?

The sexually transmitted disease (std) testing industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Product

  Laboratory testing device
  POC testing device


Disease Type

  Chlamydia
  Gonorrhea
  Syphilis
  Trichomoniasis
  Others


End-User

  Hospitals & Clinics
  Diagnostic Laboratories
  Home Care Settings
  Research & Academic Institutes


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  Middle East and Africa

    Egypt
    KSA
    Oman
    UAE


  APAC

    China
    India
    Japan


  South America

    Argentina
    Brazil


  Rest of World (ROW)

By Product Insights

The laboratory testing device segment is estimated to witness significant growth during the forecast period.

The global STD testing market is experiencing significant growth due to the rising prevalence of sexually transmitted diseases (STDs), driven primarily by unprotected sex. Approximately 376 million new cases of STDs occur annually, with genital herpes, chlamydia, and gonorrhea being the most common. In response to this public health concern, various diagnostic techniques are being employed, including blood sample testing, genital swab collection, urine sample analysis, and antibody detection assays. The industry's expansion is further fueled by the increasing emphasis on preventative healthcare, stringent sexual health education, and the availability of rapid diagnostic tests. For instance, quantitative diagnostic results, such as viral load monitoring and genotyping, offer more precise and actionable information for clinical decision support.

Qualitative diagnostic results, like immunochromatographic assays, provide quick and easy-to-interpret results, making them ideal for point-of-care diagnostics. The introduction of molecular diagnostic techniques, such as polymerase chain reaction (PCR) and nucleic acid sequence-based amplification (NASBA), has significantly improved test sensitivity metrics and accuracy. These advancements enable early detection and effective treatment, reducing the false positive rate and false negative rate. Infection control measures, including disease prevalence estimates and test result reporting, are essential components of public health surveillance. Healthcare resource allocation and treatment guidelines are continually evolving to address the challenges posed by STDs, ensuring patient confidentiality and maintaining data privacy regulations.

Prevention strategies, such as condom use and vaccinations, play a crucial role in reducing the spread of STDs. Clinical decision support systems and test specificity metrics help healthcare professionals make informed decis

Comprehensive dataset containing 24 verified STD testing service businesses in Tokyo, Japan with complete contact information, ratings, reviews, and location data.

Comprehensive dataset containing 45 verified STD testing service businesses in Japan with complete contact information, ratings, reviews, and location data.

Comprehensive dataset containing 73 verified STD clinic businesses in Japan with complete contact information, ratings, reviews, and location data.

Japan WHO Health Indicators

Substance Abuse, Mental Health, and Disease Statistics

By Humanitarian Data Exchange [source]

About this dataset

This dataset from the World Health Organization’s data portal contains a wide array of health indicators for Japan, covering topics such as mortality and global health estimates, sustainable development goals, millennium development goals, health systems, infectious diseases, health financing, public health and environment, substance use and mental health, tobacco use and violence prevention , HIV/AIDS and other sexually-transmitted infections (STIs), nutrition intake levels, urban healthcare practices,, noncommunicable disease management methods , neglected tropical diseases surveillance infrastructure statistics medical equipment technology demographic profiles , youth healthcare access policies international he Heath regulations monitoring framework insecticide resistance protocol oral health advancements Universal Health Coverage (UHC) strategies financial protection AMR GLASS ICD SEXUAL AND REPRODUCTIVE HEALTH resources. The dataset also provides links to individual indicator metadata. Please note that additional information regarding each indicator is available in those resource descriptions. Information was sourced from the WHO database and was last updated on 2020-09-16

More Datasets

For more datasets, click here.

Featured Notebooks

• 🚨 Your notebook can be here! 🚨!

How to use the dataset

This dataset provides a wealth of information about the health and safety indicators in Japan. It contains data from World Health Organization's (WHO) data portal, covering multiple categories such as mortality and global health estimates, sustainable development goals, millennium development goals (MDGs), malaria and tuberculosis, child health, infectious diseases, world health statistics, demography and socioeconomic statistics etc. This guide will provide an overview of the content of this dataset as well as instructions on how to use it.

The dataset consists of several columns which describe various aspects of each indicator: GHO Code – The code for the Global Health Observatory indicator; GHO Display – The name of the Global Health Observatory indicator; GBDChildCauses (CODE) – The code for the Global Burden of Disease Child Causes Indicator; GBDChildCauses (DISPLAY) – The name of the Global Burden Of Disease Child Causes Indicator; PublishState (CODE) - The code for the publication state; PublishState(DISPLAY)-The name of the publication state; Year(CODE)-The code for year;; Year(DISPLA & YEAR)(URL); Region(CODE & REGION)(DISPL ®ION)(URL); Country (& COUNTRY)(DISPL & COUNTRY)(URL); AgeGroup (& AGEGROUP)(COD &AGEGROUP); Sex ((SEX CODE))  Sex DISPLAY ; GHECAUSES&GHECause(DisplayGHEconse URL&CHILDCause Code cCHILDCUSE DISP、 CHILDCUSE URL Display Value、Numericlow HIGH  STD ERR StdDev Comments。

In order to begin using this dataset you will have to download it from Kaggle. After downloading you can view its contents using any application like a spreadsheet. You can also rewrite all or part of it into other formats such as JSON if necessary. Once completed follow these steps to get analytics about your data:

• Preparing Your Data - Start by eliminating all irrelevant columns that don't contain useful information or could potentially confuse or mislead your analysis process like comments column which contain notes on certain entries in this set rather than numbers or statistical values related to them..

• Calculate/ Analyze relevant indicators - Use function formulas that come with your application suite like average median mode min max calculations etc so that you can know exactly what kindof , indicators is being used in

Research Ideas

• Analysis of healthcare improvements or shortfalls across Japan over time.
• Tracking the prevalence of various types of Noncommunicable Diseases (NCDs) in Japan, including mental health issues, to inform public policy and interventions.
• Examination of the infrastructure spending in Japanese healthcare to help inform other nations’ decisions on investment levels for health services delivery

Acknowledgements

If you use this dataset in your research, please credit the original authors. Data Source

License

See the dataset description for more information.

Columns

File: all-health-indicators-for-japan-18.csv | Column name | Description | |:-----------------------------|:------------------------------------------------------------------...

Background Amebiasis, which is caused by Entamoeba histolytica, is a re-emerging public health issue owing to sexually transmitted infection (STI) in Japan. However, epidemiological data are quite limited. Methods To reveal the relative prevalence of sexually transmitted E. histolytica infection to other STIs, we conducted a cross-sectional study at a voluntary counselling and testing (VCT) centre in Tokyo. Seroprevalence of E. histolytica was assessed according to positivity with an enzyme-linked immunosorbent assay for E. histolytica-specific IgG in serum samples collected from anonymous VCT clients. Results Among 2,083 samples, seropositive rate for E. histolytica was 2.64%, which was higher than that for HIV-1 (0.34%, p < 0.001) and comparable to that for syphilis (rapid plasma reagin (RPR) 2.11%, p = 0.31). Positivity for Chlamydia trachomatis in urine by transcription-mediated amplification (TMA) was 4.59%. Seropositivity for E. histolytica was high among RPR- or Treponema pallidum hemagglutination (TPHA)-positive individuals and it was not different between clients with and without other STIs. Both seropositivity of E. histolytica and RPR were high among male clients. The seropositive rate for anti-E. histolytica antibody was positively correlated with age. TMA positivity for urine C. trachomatis was high among female clients and negatively correlated with age. Regression analysis identified that male sex, older age, and TPHA-positive results are independent risk factors of E. histolytica seropositivity. Conclusions Seroprevalence of E. histolytica was 7.9 times higher than that of HIV-1 at a VCT centre in Tokyo, with a tendency to be higher among people at risk for syphilis infection. There is a need for education and specific interventions against this parasite, as a potentially re- 65 emerging pathogen.

Methods The design of this study was a cross-sectional study. The total 2,083 serum samples used in this study were collected at the Tokyo Metropolitan Minami Shinjuku Testing – Counselling Centre where more than 10,000 anonymous clients seek HIV-1 screening tests each year. Collected samples are transferred to the Tokyo Metropolitan Institute of Public Health for laboratory testing, then stored at 4°C. Fourth generation HIV-1 screening is performed routinely throughout the year. However, in 2 months of the year (e.g., June and December in the case of 2017), the Tokyo Metropolitan Government intensifies STI screening, and rapid plasma reagin (RPR) and Treponema pallidum hemagglutination (TPHA) tests for syphilis screening are additionally performed for all clients. In addition, urinary sampling and transcription-mediated amplification (TMA) assay testing for Chlamydia trachomatis and Neisseria gonorrhoeae are performed for clients who are willing to undergo these tests.

The STD Diagnostics Market is set to grow from USD 7.8 Billion in 2025 to USD 18.6 Billion by 2035, driven by rising awareness, at an 8.2% CAGR.

At-Home STI Testing Platforms Market Outlook

According to our latest research, the Global At-Home STI Testing Platforms market size was valued at $1.1 billion in 2024 and is projected to reach $5.7 billion by 2033, expanding at a CAGR of 20.3% during 2024–2033. The primary driver fueling the rapid expansion of this market is the increasing emphasis on privacy, convenience, and early detection in sexual health management, which has catalyzed the adoption of at-home STI testing solutions worldwide. As awareness about sexually transmitted infections (STIs) rises and stigmas associated with clinical testing persist, consumers are increasingly seeking discreet, reliable, and accessible alternatives. Technological advancements, coupled with growing digital health infrastructure, have further simplified sample collection, result delivery, and telehealth integration, making at-home STI testing platforms a pivotal component in the modern healthcare landscape.

Regional Outlook

North America currently holds the largest share of the global At-Home STI Testing Platforms market, accounting for approximately 45% of total market value in 2024. This dominance is attributed to a highly mature digital health ecosystem, robust healthcare infrastructure, and proactive regulatory frameworks that support direct-to-consumer health models. The presence of leading market players, high consumer awareness, and widespread adoption of telemedicine services further bolster regional growth. Favorable reimbursement policies and continuous investment in healthcare innovation have enabled seamless integration of at-home testing platforms with digital health records and telehealth consultations. The United States, in particular, demonstrates strong demand due to its progressive approach to sexual health, ongoing public health campaigns, and a high rate of internet penetration, which facilitates the distribution and utilization of digital platforms and test kits.

The Asia Pacific region is expected to witness the fastest growth, with a projected CAGR exceeding 24% during the forecast period. This surge is driven by increasing urbanization, expanding middle-class populations, and rapidly improving digital infrastructure across major economies such as China, India, Japan, and South Korea. Government initiatives aimed at promoting sexual health awareness, coupled with rising smartphone penetration, are enabling broader access to digital testing solutions. Additionally, the region is experiencing a surge in venture capital investments and strategic partnerships focused on expanding telehealth and e-pharmacy services. Local startups and global market entrants are leveraging these trends to introduce innovative, cost-effective, and culturally tailored at-home STI testing products, addressing unmet needs and overcoming traditional barriers to STI diagnosis.

Emerging economies in Latin America and the Middle East & Africa are gradually adopting at-home STI testing platforms, albeit at a slower pace due to infrastructural and socio-cultural challenges. In these regions, limited healthcare access, lower digital literacy rates, and prevailing stigmas around sexual health create significant barriers to widespread adoption. However, targeted public health initiatives, international collaborations, and the entry of multinational digital health companies are beginning to address these challenges. Localized demand, particularly among urban youth and tech-savvy populations, is fostering incremental market growth. Policy reforms aimed at improving healthcare accessibility and integrating telemedicine into national health strategies are expected to gradually enhance market penetration in these emerging regions.

Report Scope

Elucidation of the structure of human sexual networks is not only an interesting topic in the area of social networks but also an important clue for understanding the spreading risk of sexually transmitted infections (STIs). Some previous studies have indicated that sexual networks are scale free, while others have suggested that they are not. We conducted a Web-based survey on sexual contact in Japan to collect data on cumulative (total) heterosexual partners and the number of recent (in the last three or previous three months) heterosexual partners. To determine whether the number of heterosexual contacts in Japan has a power-law tail, we used maximum likelihood fitting methods and Kolmogorov-Smirnov tests. For confirmation, we also used the Akaike information criterion (AIC) and the Bayesian information criterion (BIC). Our results indicate that the distributions of the number of sexual partners in Japan have power-law tails.

11 Global import shipment records of Std Accessories with prices, volume & current Buyer's suppliers relationships based on actual Global export trade database.

Comprehensive dataset containing 1 verified STD clinic businesses in Hyogo, Japan with complete contact information, ratings, reviews, and location data.

Snapshot img

Socially Stigmatized Diseases Market Size 2024-2028

The socially stigmatized diseases market size is forecast to increase by USD 343.5 billion, at a CAGR of 8.2% between 2023 and 2028.

The market is experiencing significant growth due to several key factors. One of the primary drivers is the high prevalence of diseases such as HIV and AIDS, which necessitates the development of effective treatments and delivery routes. Another trend is the increasing availability of medication for these diseases online, making it more accessible to those who may face social stigma or geographical barriers. However, there are also challenges that must be addressed, including bottlenecks in the supply chain and the persistent social stigma surrounding these diseases, which can hinder access to healthcare and treatment. To address these challenges, it is essential to focus on improving delivery routes and addressing the root causes of social stigma. By doing so, we can ensure that those in need have access to the care and treatment they require, ultimately leading to better health outcomes and a reduced burden on healthcare systems.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market encompasses a range of health conditions that carry a significant social stigma, often leading to discrimination and marginalization. Effective data management and real-time analytics are crucial for understanding the dynamics of these diseases, improving public health interventions, and mitigating their societal impact. Data management in the market faces unique challenges. The lack of standardization in data collection, storage, and sharing across various industries and sectors hampers comprehensive disease surveillance and response efforts. Moreover, the sensitive nature of medical information associated with these diseases necessitates strong data security measures. Graph databases and property graph models offer promising solutions to address these challenges. Graph databases enable efficient handling of complex relationships between vertices (nodes) and edges (connections) in data. Labels can be assigned to vertices to represent different disease entities, while indexes facilitate rapid data retrieval.
In the market, long tasks and stored procedures are essential for processing large volumes of data in real-time. Real-time analytics enables logistics professionals in the finance and logistics industries to optimize routes, manage warehouses, and ensure efficient disease surveillance. The finance industry can leverage data modeling and visualization tools to identify patterns and trends in financial transactions related to socially stigmatized diseases. This information can inform investment strategies and risk assessments. In the logistics industry, real-time analytics can optimize supply chain operations and improve response times to disease outbreaks. Data centers and cloud regions play a vital role market by providing secure, scalable, and cost-effective storage solutions. Business processes can be automated using programming ease and visualization tools, enabling more efficient data analysis and decision-making.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Disease Type

  STIs
  Mental health disorders
  Cancer
  Others


Therapy

  Medications
  Therapy and counseling
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Disease Type Insights

The STIs segment is estimated to witness significant growth during the forecast period.

Sexually transmitted infections (STIs), also known as sexually transmitted diseases (STDs), are a significant sector within the global market for socially stigmatized diseases. These infections are contracted through sexual contact, affecting various parts of the body including the mouth, anus, vagina, and penis. STIs encompass a range of conditions, each presenting unique symptoms and health consequences. Common symptoms include discomfort such as burning sensations and itching in the genital area, as well as discharge. In India, as of 2023, the prevalence of STIs is substantial, with around 6% of the adult population reportedly affected by one or more STIs or reproductive tract infections (RTIs). This equates to approximately 30 to 35 million cases annually, underscoring the considerable public health challenge posed by these infections.

Get a glance at the market report of share of various segments Request Free Sample

The STIs segment was valued at USD 254.10 billion in 2018 and show